Fellow

Chris Griffiths is Professor of Dermatology at the University of Manchester. He is distinguished for his introduction of the concept of therapeutic targeting of immunological processes in psoriasis, and for understanding the mechanisms of cutaneous photodamage. His research on the efficacy of ciclosporin demonstrated the importance of immune mechanisms, overturning the earlier view that it was primarily an epidermal disease. His observation of the importance of adhesion-molecule expression in psoriasis led to the development of efalizumab for the treatment of psoriasis. His clinical trials for biologic treatment for psoriasis have formed the basis for NICE guidance.